ClinicalTrials.gg
Not yet recruitingNCT07944014Updated Nov 18, 2026

Portfolio Diet for Dyslipidemia: A Hong Kong Pilot Study

An interventional study of Culturally Adapted Portfolio Diet Health Education Programme in Dyslipidemias and Hyperlipidemias, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionHyperlipidemiasRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hyperlipidemias
Why
  1. The study's listed conditions name Hyperlipidemias, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 95 studies in Hyperlipidemias with a site in China — 30 open to participants now, 38 under way, 7 of them phase 3. Hyperlipidemias · China.

Planned enrollment
76th of 79
12 · median 150
Started
2027
the only one that year
No phase
21 of 95
10 open now
Primary completion
2027-12
later than 26 of 37 live
Registered
95th of 95
by date

Among the 95 studies in Hyperlipidemias with a site in China, this one is the 76th largest by planned enrollment of the 79 interventional ones that give a count, is the only one that started in 2027, is one of 21 with no phase, reaches primary completion later than 26 of the 37 other live ones, and was the 95th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 95 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

Background:

Dyslipidemia (raised blood cholesterol) is a widespread public health concern in Hong Kong. While medications like statins are commonly used, many individuals hesitate to take them, making effective dietary strategies essential for reducing cardiovascular disease risk. The Portfolio Diet is a proven plant-based dietary pattern that can significantly lower cholesterol levels, but its feasibility has not yet been thoroughly explored or culturally adapted for a non-Western population like Hong Kong.

Purpose:

This feasibility study aims to evaluate whether a culturally tailored Portfolio Diet health education programme is practical, acceptable, and effective for Hong Kong adults with dyslipidemia. The findings will help researchers understand the practical challenges and motivators participants face when trying to change their diet, which will guide the design of a future larger-scale trial.

Methods:

A total of 12 Chinese adults aged 18 to 65 with borderline or high total cholesterol will participate in a 4-week health education programme. The programme begins with a group session explaining the core dietary principles, followed by 3 weekly individual dietary consultations with a research dietitian. The diet plan and sample 7-day menus are culturally adapted to include food items commonly consumed in Chinese culture.

Participants' diet adherence will be assessed using 3-day dietary records at the beginning and end of the study. Additionally, researchers will track feasibility data such as recruitment and retention rates, session attendance, and the completeness of the dietary records. Following the 4-week programme, participants will join focus group interviews to share their personal feedback, experiences, and suggestions for improving the programme for long-term use.

Read the detailed description

Background and Rationale:

Dyslipidemia is a major public health challenge in Hong Kong, affecting over half of the adult population. While standard management relies on lifestyle advice and pharmacotherapy (e.g., statins), patient hesitancy toward medication remains a significant barrier. The Portfolio Diet-a dietary pattern combining four cholesterol-lowering components (viscous fibers, plant sterols, plant proteins, and nuts)-has demonstrated clinical efficacy in reducing serum low-density lipoprotein-cholesterol (LDL-C) by a mean of 28.6% in Western cohorts. However, its feasibility, acceptability, and efficacy signal have not been explored in non-Western populations whose local dietary habits differ significantly. This feasibility study is a necessary prerequisite to adapt the dietary components into Chinese culture and inform the design of a future full-scale randomized controlled trial (RCT).

Objectives:

  1. To evaluate the feasibility and process metrics (recruitment, retention, and session attendance rates) of a culturally adapted Portfolio Diet health education programme.
  2. To assess the acceptability and participant burden (completion and compliance rates of 3-day dietary records).
  3. To explore the preliminary efficacy signal of the programme in improving Portfolio Diet adherence among Hong Kong adults with dyslipidemia.
  4. To identify facilitators and barriers to dietary change through qualitative feedback to enhance the future intervention plan.

Study Design and Interventions:

This is an interventional feasibility study utilizing a single-group, pre-post test design combined with a qualitative component. Twelve eligible Chinese adults with dyslipidemia will undergo a 4-week health education programme:

  • Week 1 (Group Session): Introduction to the principles of the Portfolio Diet, its cholesterol-lowering mechanisms, and its relationship with cardiometabolic health.
  • Weeks 2-4 (Individual Consultations): Three weekly sessions of personalized dietary consultations conducted by a research dietitian. Participants will receive a culturally tailored 7-day menu adjusted to commonly consumed food groups in Chinese culture, targeting five dietary pillars: nuts/seeds (45 g/day), plant protein (50 g/day), viscous fiber (20 g/day), plant sterols (2 g/day), and monounsaturated fatty acid-rich plant fats (45 g/day).

Qualitative Component:

Post-intervention, all 12 participants will be divided into two focus groups (6 participants per group) for a 1-hour semi-structured interview conducted by a trained research assistant. The interviews will be audio-recorded and will systematically explore four domains: programme acceptability, dietary changes and practicality, perceived benefits, and suggestions for long-term implementation in Hong Kong.

Data Collection and Dietary Analysis:

Quantitative clinical and socio-demographic data will be collected at baseline and at week 4 (post-intervention). Dietary adherence will be assessed using 3-day dietary records (2 weekdays and 1 weekend day) completed at both time points. Nutrient and individual component intakes will be rigorously analyzed using Food Processor Nutrition Analysis and Fitness software (Version 8.0, ESHA Research), utilizing localized food composition tables from China and Hong Kong to ensure accuracy.

03

Conditions studied

  • Dyslipidemias
  • Hyperlipidemias

Browse trials for

Keywords

  • Portfolio Diet
  • Dyslipidemias
  • Hypercholesterolemia
  • Health Education
  • Dietary Adherence
04

In context

Hyperlipidemias Reclassified

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

This study's planned enrollment of 12 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.

Browse Hyperlipidemias studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 683 studies on the registry; 261 are open to participants now.

Compared within Hyperlipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years.
  • Of Chinese ethnicity.
  • Diagnosed with borderline or high total cholesterol (TC ≥ 5.2 mmol/L).
  • Overweight or obese, defined as a (BMI) ≥ 23 kg/m2.
  • Currently residing in Hong Kong with no travel plans for the following 12 weeks.
  • Able and willing to maintain a regular lifestyle and eating habits throughout the study period.
  • Capable of providing voluntary written .

Exclusion criteria

Exclusion Criteria:

  • Known history of alcohol, cigarette, or drug abuse within the past 3 months.
  • Known liver and/or renal dysfunction.
  • Known history of severe medical conditions (e.g., cardiovascular disease, diabetes, inflammatory bowel disease, cancer, or psychiatric illness).
  • Participation in any other interventional clinical trials within the past 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Portfolio Diet Education Group

    A single group of 12 Hong Kong Chinese adults with dyslipidemia who receive a culturally adapted 4-week Portfolio Diet health education programme, followed by qualitative focus group interviews.

    Behavioral: Culturally Adapted Portfolio Diet Health Education Programme

Interventions

  • BehavioralCulturally Adapted Portfolio Diet Health Education Programme

    The programme consists of 4 weekly sessions. Week 1 is a group-based session introducing the principles of the Portfolio Diet and its clinical relationship with cardiometabolic health. Weeks 2 to 4 consist of 3 individual dietary consultations conducted by a research dietitian. The dietary components (nuts/seeds, plant protein, viscous fiber, plant sterols, and plant-based fats) are culturally adapted to commonly consumed food groups in Chinese culture. Participants receive a localized 7-day menu to help modify their diet.

07

What researchers measure

Primary outcomes

  1. Programme Retention Rate

    The percentage of enrolled participants who successfully complete the entire 4-week health education programme. This metric is used to evaluate the feasibility of the study protocol and participant retention.

    Time frame: At the end of the 4-week intervention

  2. Change in Portfolio Diet Adherence Score

    Assessed by 3-day dietary records (covering 2 weekdays and 1 weekend day) to evaluate the change in participant adherence to the Portfolio Diet pillars. Nutrient and dietary component intakes will be analyzed using Food Processor Nutrition Analysis and Fitness software (Version 8.0) with localized food composition tables.

    Time frame: Baseline and Post-intervention (Week 4)

Secondary outcomes

  1. Participant Acceptability and Perceived Barriers via Focus Groups

    Evaluated through post-intervention qualitative focus group interviews (6 participants per group). A semi-structured interview guide will be used to explore four core domains: acceptability of the programme format/duration, dietary changes and practical challenges, perceived health benefits, and suggestions for long-term implementation.

    Time frame: Post-intervention (Week 4)

08

Study locations

1 site
  • Department of Food Science and Nutrition, The Hong Kong Polytechnic University
    Hong Kong, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — As this is a small-scale pilot feasibility study (N=12) focused on evaluating protocol processes and cultural acceptability, individual participant data will not be made publicly available to protect participant privacy.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 166 non-industry interventional studies with no phase under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 11 months is below that.

Counting every sponsor, half of 171 studies reached it within 15 months; a quarter within 7 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07944014
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Ka-hei Kenneth Lo, PhD
Contact
kenneth.kh.lo@polyu.edu.hk
+852 3400 8778

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion